The patients were randomized in a 3:1:1 ratio to receive ipilimumab with the melanoma peptide vaccine gp100 (n = 403), ipilimumab with gp100 placebo (n = 137), or gp100 vaccine with ipilimumab placebo (n = 136). This evidence concerns the gene PMEL and melanoma.